[Funding alert] Dutch-based Matisse Pharmaceuticals Raises €3.6M in Fresh Funding

The fresh new funding will allow Matisse to effectively continue its preparation for a large scale phase II study in sepsis patients. In the course of 2024, Matisse aims to conclude a series A funding round which should cover the full execution of the mentioned phase II clinical trial, the scale up of production to a commercial scale level and to progress on a number of R&D projects, thereby also further strengthening the organization.

Read also - UK-based Technology Company Travelport Secures $570m in New Equity Funding

Matisse will shortly be able to announce the results of the phase 1/2a Histoseps trial in sepsis patients, which is a major milestone for the company.

Marcel Jacobs, CEO of Matisse Pharmaceuticals said, “We are thankful for the confidence of our existing and new investors in our company and developments. Being able to close this round just before a major milestone publication and in a difficult 2023 biotech funding environment, underpins the support for and importance of finding a solution for treating sepsis”,.

Read also - Lyon-based ENYO Pharma Secures a €39 Million in Series C Round Funding

About Matisse Pharmaceuticals

Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main development program is the development of a medicine to fight sepsis and septic shock.

Read also - Mental Health Startup Self Space Secures €2.6 million Seed Funding